COVID-19 is announced as a global pandemic in 2020. Its mortality and morbidity rate are
rapidly increasing, with limited medications. The emergent outbreak of COVID-19 prompted …

Abstract Background and Objective Ruxolitinib is a tyrosine kinase inhibitor targeting the
Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways …

We are witnessing a paradigm shift in drug development and clinical practice to fight the
novel coronavirus disease (COVID-19), and a number of clinical trials have been or are …

Many drugs are being administered to tackle coronavirus disease 2019 (COVID-19)
pandemic situations without establishing clinical effectiveness or tailoring safety. A …

The landscape of medical treatments is undergoing a transformative shift. Precision
medicine has ushered in a revolutionary era in healthcare by individualizing diagnostics and …

Glofitamab is a novel T cell bispecific antibody developed for treatment of relapsed‐
refractory diffuse large B cell lymphoma and other non‐Hodgkin's lymphoma indications. By …

The inhibition of cytochrome P450 (CYP) enzymes is the most frequent cause of drug–drug
interactions. Many safe, inexpensive and widely available therapeutic drugs can inhibit CYP …

Renal (RIP) and hepatic (HIP) impairments are prevalent conditions in cancer patients. They
can cause changes in gastric emptying time, albumin levels, hematocrit, glomerular filtration …

Pharmacokinetic characterization plays a vital role in drug discovery and development.
Although involving numerous laboratory animals with error-prone, labor-intensive, and time …

Purpose Ruxolitinib is metabolized by cytochrome P450 (CYP) 3A4 and CYP2C9. Dual
inhibitors of these enzymes (like fluconazole) lead to increased ruxolitinib exposure relative …